Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.01 | -0.00 |
| FCF Yield | -93.17% | -45.11% | -93.72% | -41.73% |
| EV / EBITDA | 3.48 | -1.17 | 0.25 | 0.29 |
| Quality | ||||
| ROIC | -17.49% | 1,074.14% | -987.21% | -85.88% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.89 | 0.90 | 0.69 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -90.96% | 27.03% | -59.15% | 45.27% |
| Safety | ||||
| Net Debt / EBITDA | 5.51 | 0.83 | 0.99 | 1.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -120,592.59 | -119,674.86 | -38,106.40 |